Senescence as a main mechanism of Ritonavir and Ritonavir‐NO action against melanoma
- 17 April 2019
- journal article
- research article
- Published by Wiley in Molecular Carcinogenesis
- Vol. 58 (8) , 1362-1375
Abstract
The main focus of this study is exploring the effect and mechanism of two HIV‐protease inhibitors: Ritonavir and Ritonavir‐nitric oxide (Ritonavir‐NO) on in vitro growth of melanoma cell lines. NO modification significantly improved the antitumor potential of Ritonavir, as the IC50 values of Ritonavir‐NO were approximately two times lower than IC50 values of the parental compound. Our results showed for the first time, that both compounds induced senescence in primary and metastatic melanoma cell lines. This transformation was manifested as a change in cell morphology, enlargement of nuclei, increased cellular granulation, upregulation of β‐galactosidase activity, lipofuscin granules appearance, higher production of reactive oxygen species and persistent inhibition of proliferation. The expression of p53, as one of the key regulators of senescence, was upregulated after 48 hours of Ritonavir‐NO treatment only in metastatic B16F10 cells, ranking it as a late‐response event. The development of senescent phenotype was consistent with the alteration of the cytoskeleton—as we observed diminished expression of vinculin, α‐actin, and β‐tubulin. Permanent inhibition of S6 protein by Ritonavir‐NO, but not Ritonavir, could be responsible for a stronger antiproliferative potential of the NO‐modified compound. Taken together, induction of senescent phenotype may provide an excellent platform for developing therapeutic approaches based on selective killing of senescent cells.Keywords
Funding Information
- Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja ([grant numbers 173013 and 41031])
This publication has 83 references indexed in Scilit:
- Notch post-translationally regulates β-catenin protein in stem and progenitor cellsNature Cell Biology, 2011
- Caspase 3–mediated stimulation of tumor cell repopulation during cancer radiotherapyNature Medicine, 2011
- The Human Immunodeficiency Virus Protease Inhibitor Ritonavir Inhibits Lung Cancer Cells, in Part, by Inhibition of SurvivinJournal of Thoracic Oncology, 2011
- Regulation of Ribosomal Protein S6 Phosphorylation by Casein Kinase 1 and Protein Phosphatase 1Journal of Biological Chemistry, 2011
- Therapy-Induced Senescence in CancerJNCI: Journal of the National Cancer Institute, 2010
- Senescence in tumours: evidence from mice and humansNature Reviews Cancer, 2010
- Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cellsMolecular Cancer, 2009
- Repositioning HIV protease inhibitors as cancer therapeuticsCurrent Opinion in HIV and AIDS, 2008
- Cellular senescence and chromatin organisationBritish Journal of Cancer, 2007
- Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomasNature, 2007